ArticleMedicine2026
Sijunzi decoction ameliorates geriatric sarcopenia by improving muscle strength, quality, and functions.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTo study the therapeutic efficacy and its mechanism of Sijunzi decoction (SJZD) in geriatric sarcopenia.
methodsGeriatric sarcopenia patients were divided into control group (n = 31) and research group (n = 31). Control group received basic intervention therapy, research group received basic intervention therapy and SJZD. Clinical efficacy (AMIS, 6 meters walking speed, and grip strength), comprehensive geriatric assessment (activities of daily living, Morse, mini-nutritional assessment, Frail, mini-mental state examination, self-rating anxiety scale, and geriatric depression scale), the functions of liver and kidney, blood cells inflammatory indexes (platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, systemic immune-inflammatory index, systemic inflammation response index, and aggregate inflammation systemic index), and nutritional indicators were detected. Network pharmacology was used to study the mechanism of SJZD in treating sarcopenia.
resultsAfter SJZD treatment, the levels of AMIS, 6 meters walking speed, and grip strength, the scores of activities of daily living, mini-nutritional assessment, and mini-mental state examination scale were significantly increased, compared with the control group, while the scores of Morse, Frail, self-rating anxiety scale, and geriatric depression scale were strongly decreased. The levels of aspartate aminotransferase, alanine aminotransferase, hemoglobin, albumin, prealbumin, and body mass index in research group were obviously higher than that in control group, but the levels of blood urea nitrogen, creatinine, platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, systemic immune-inflammatory index, systemic inflammation response index, and aggregate inflammation systemic index were obviously decreased after treatment. Network pharmacology results showed that the active ingredients of SJZD acted on 36 targets of sarcopenia, which were mainly enriched in the interleukin-17 pathway, TNF pathway. We also found that the serum levels of interleukin-1β, matrix metalloprotein-9, tumor necrosis factor-α, interleukin-6, myostatin, and C-reactive protein were significantly reduced by SJZD, which suggested the roles of SJZD in inflammation.
conclusionSJZD improved muscle strength, quality, and functions in sarcopenia patients by reducing peripheral blood inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.